C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2026)

C4 Therapeutics has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $15.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 38.53% year-over-year to $15.4 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (down 38.53% YoY), and the FY2025 full-year result was $15.8 million, down 44.33% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $15.4 million, down from $15.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $28.6 million in Q3 2024, with the low at $15.4 million in Q1 2026.
• Average Non-Current Deffered Revenue over 5 years is $20.3 million, with a median of $19.6 million recorded in 2023.
• Year-over-year, Non-Current Deffered Revenue sank 62.62% in 2022 and soared 45.99% in 2024.
• Tracing CCCC's Non-Current Deffered Revenue over 5 years: stood at $16.9 million in 2022, then rose by 29.12% to $21.8 million in 2023, then jumped by 30.45% to $28.5 million in 2024, then tumbled by 44.33% to $15.8 million in 2025, then dropped by 2.53% to $15.4 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $15.4 million (Q1 2026), $15.8 million (Q4 2025), and $19.9 million (Q3 2025), per Business Quant data.

Peer Comparison